Pharma Focus Europe

AlzeCure's Alzheimer project NeuroRestore ACD856 is also granted a European patent

Monday, May 22, 2023

AlzeCure Pharma AB (publ) (FN STO: ALZCUR) developing small molecule drug candidates for CNS diseases, focusing on Alzheimer's disease and pain, announced today that the European Patent Office (EPO) has granted a patent covering the company's drug candidate ACD856, which is developed against Alzheimer's and other disorders with cognitive impairment.

"This is another important step for ACD856, considering that we have already been granted a US patent for this substance. Now we strengthen the patent portfolio for our NeuroRestore program even more", says Gunnar Nordvall, Head of Chemistry and IP at AlzeCure Pharma.

The company's patent application for ACD856 in Europe has been granted by the EPO and validated in 33 territories across Europe, including Germany, France, the UK, Spain, Italy and Sweden. ACD856, the lead drug candidate in the NeuroRestore platform, is being developed against Alzheimer's disease. The patent number is 3,759,088 and the patent is expected to provide protection until 2039.

"This is an important milestone for both the project and the company and further strengthens our commercial opportunities for ACD856 in areas with very large medical needs, such as Alzheimer's and depression," says AlzeCure CEO Martin Jönsson.

ACD856 and other substances from the NeuroRestore platform stimulate several important signaling systems and signaling substances in the brain such as BDNF ( Brain Derived Neurotrophic Factor ) and NGF ( Nerve Growth Factor ), which can lead to improved cognition. Previous preclinical studies have shown that AlzeCure's drug candidates strengthen communication between nerve cells and improve cognitive ability, including learning and memory functions.

ACD856 recently completed phase I clinical studies, where both good safety and tolerability were demonstrated in humans, but also that the drug candidate crossed the blood-brain barrier and that the substance activated parts of the brain that are central to both cognition and depression treatment. New preclinical results also show potential neuroprotective and disease-modifying effects with these substances, which can be very significant for the project.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva